Severe Hemophilia A research hub

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

This study looks at how a medicine called emicizumab affects the overall health, activity levels, and joints of people with moderate or severe haemophilia A. It's for those already receiving another treatment and planning to switch to emicizumab.